KRIM-1 Activators
KRIM-1 Activators encompass a range of chemical compounds that indirectly stimulate the functional activity of KRIM-1 through diverse signaling pathways. For instance, Forskolin, by increasing cAMP levels, and IBMX, through inhibition of PDEs, both result in the activation of PKA, which may phosphorylate and thereby activate KRIM-1. Similarly, the use of PMA activates PKC, which could lead to the phosphorylation and subsequent enhancement of KRIM-1's function. Ionomycin and A23187 act as calcium ionophores, elevating intracellular calcium levels, which in turn can activate calmodulin-dependent kinases that might phosphorylate KRIM-1, enhancing its activity. On the other hand, Genistein by inhibiting tyrosine kinases, and Epigallocatechin gallate (EGCG) as a kinase inhibitor,could potentially reduce competitive inhibitory signaling, indirectly augmenting KRIM-1 activity, assuming KRIM-1 is regulated by such kinases or is part of a pathway antagonized by them. Sphingosine-1-phosphate, through its receptors, may activate downstream kinases such as PKC or Akt, which could in turn activate KRIM-1 or modulate its regulators, enhancing KRIM-1's functional role. Thapsigargin further contributes to KRIM-1 activation by increasing cytosolic calcium, which then activates calcium-dependent kinases, potentially leading to the phosphorylation or interaction enhancement of KRIM-1.
Continuing with the theme of kinase modulation, LY294002 and U0126 each inhibit a component of cell signaling pathways (PI3K/Akt and MEK/ERK, respectively); their inhibition may lead to an upregulation of KRIM-1's activity if KRIM-1 is part of a compensatory pathway or if it is negatively regulated by these pathways. Staurosporine, although a broad-spectrum kinase inhibitor, may selectively enhance KRIM-1 activity by inhibiting kinases that negatively regulate KRIM-1 or its associated pathways. Collectively, these KRIM-1 Activators exert their influence on cellular signaling networks, potentially leading to the enhanced activity of KRIM-1 through indirect mechanisms that involve modulation of kinases, phosphatases, or other proteins that interact with or regulate KRIM-1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases (PDEs) leading to increased cAMP and cGMP levels in cells. The accumulation of these cyclic nucleotides indirectly enhances KRIM-1 activity by cAMP- or cGMP-dependent protein kinase pathways such as PKA and PKG. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) is a potent activator of protein kinase C (PKC). Activation of PKC can lead to phosphorylation of various substrates, potentially including KRIM-1, or proteins that interact with KRIM-1, thereby enhancing its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentration. Elevated calcium can activate calmodulin-dependent kinases, which may phosphorylate KRIM-1 or associated proteins, enhancing KRIM-1 activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. By inhibiting competitive tyrosine kinase signaling, it can enhance KRIM-1 activity if KRIM-1 is regulated by tyrosine phosphorylation or is part of a pathway antagonized by tyrosine kinases. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate (S1P) binds to its G protein-coupled receptors, which may lead to activation of downstream kinases such as PKC or Akt. These kinases could phosphorylate and activate KRIM-1 or modulate its regulators. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that could reduce competitive signaling pathways, potentially leading to enhanced KRIM-1 activity if KRIM-1 is negatively regulated by those pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that leads to increased cytosolic calcium. The resultant activation of calcium-dependent kinases could enhance the activity of KRIM-1 through phosphorylation or interaction with calcium-binding proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K/Akt signaling, it could enhance KRIM-1 activity if KRIM-1 functions are upregulated in response to decreased survival/proliferative signals. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, leading to decreased ERK pathway activity. If KRIM-1 is part of a pathway that is upregulated when ERK signaling is down, KRIM-1 activity could be indirectly enhanced. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. While it inhibits many kinases, it could paradoxically enhance KRIM-1 activity by inhibiting kinases that negatively regulate KRIM-1 or its pathway components. | ||||||